OBJECTIVES: Emerging evidence shows that non-nutritive sweeteners might induce glucose intolerance. This study aims to determine the effects of chronic exposure to sucralose on glycemic response, insulin secretion and sensitivity, and glucagon-like peptide-1 (GLP-1) release in healthy subjects. METHODS:Healthy volunteers who did not use non-nutritive sweeteners and were normoglycemia after oral glucose tolerance test (OGTT) were recruited. Subjects underwent a 75-g OGTT on two separate occasions, preceded by blindly consuming pills containing either 200 mg sucralose or placebo for 4 wk in a randomized crossover trial. Plasma glucose, insulin, and active GLP-1 levels were obtained after ingesting 75-g glucose. On the following day, intravenous glucose tolerance test (IVGTT) was performed to evaluate the acute insulin response (AIR). RESULTS:Fifteen participants (11 females, age 31.9 ± 10 y, body mass index 23.1 ± 3 kg/m2) participated in the study. AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001). Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005). AUC of active GLP-1 was significantly higher in the sucralose than placebo (23.16 ± 18.86 versus 18.5 ± 22.22 pmol/L ⋅ 120 min, P < 0.001). CONCLUSIONS: The continuous exposure to sucralose reduced AIR, decreased insulin sensitivity, and enhanced GLP-1 release in healthy subjects. However, the clinical significance of these results needs to be investigated in longer follow-up studies.
RCT Entities:
OBJECTIVES: Emerging evidence shows that non-nutritive sweeteners might induce glucose intolerance. This study aims to determine the effects of chronic exposure to sucralose on glycemic response, insulin secretion and sensitivity, and glucagon-like peptide-1 (GLP-1) release in healthy subjects. METHODS: Healthy volunteers who did not use non-nutritive sweeteners and were normoglycemia after oral glucose tolerance test (OGTT) were recruited. Subjects underwent a 75-g OGTT on two separate occasions, preceded by blindly consuming pills containing either 200 mg sucralose or placebo for 4 wk in a randomized crossover trial. Plasma glucose, insulin, and active GLP-1 levels were obtained after ingesting 75-g glucose. On the following day, intravenous glucose tolerance test (IVGTT) was performed to evaluate the acute insulin response (AIR). RESULTS: Fifteen participants (11 females, age 31.9 ± 10 y, body mass index 23.1 ± 3 kg/m2) participated in the study. AIR was lower after exposure to sucralose than placebo (58.9 ± 48.61 versus 69.94 ± 73.81 µU/mL, P < 0.001). Whole-body insulin sensitivity (estimated using the Matsuda index) was lower in sucralose than placebo (4.69 ± 1.67 versus 5.31 ± 2.56, P < 0.005). AUC of active GLP-1 was significantly higher in the sucralose than placebo (23.16 ± 18.86 versus 18.5 ± 22.22 pmol/L ⋅ 120 min, P < 0.001). CONCLUSIONS: The continuous exposure to sucralose reduced AIR, decreased insulin sensitivity, and enhanced GLP-1 release in healthy subjects. However, the clinical significance of these results needs to be investigated in longer follow-up studies.
Authors: Sofie Stampe; Magnus Leth-Møller; Eva Greibe; Elke Hoffmann-Lücke; Michael Pedersen; Per Ovesen Journal: Nutrients Date: 2022-06-25 Impact factor: 6.706
Authors: Joan Serrano; Kathleen R Smith; Audra L Crouch; Vandana Sharma; Fanchao Yi; Veronika Vargova; Traci E LaMoia; Lydia M Dupont; Vanida Serna; Fenfen Tang; Laisa Gomes-Dias; Joshua J Blakeslee; Emmanuel Hatzakis; Scott N Peterson; Matthew Anderson; Richard E Pratley; George A Kyriazis Journal: Microbiome Date: 2021-01-12 Impact factor: 14.650
Authors: Allison C Sylvetsky; Hailey R Moore; Jasmine H Kaidbey; Sabrina E Halberg; Fran R Cogen; Loretta DiPietro; Angelo Elmi; Michael I Goran; Randi Streisand Journal: Contemp Clin Trials Date: 2021-05-08 Impact factor: 2.261
Authors: Angélica Y Gómez-Arauz; Nallely Bueno-Hernández; Leon F Palomera; Raúl Alcántara-Suárez; Karen L De León; Lucía A Méndez-García; Miguel Carrero-Aguirre; Aaron N Manjarrez-Reyna; Camilo P Martínez-Reyes; Marcela Esquivel-Velázquez; Alejandra Ruiz-Barranco; Neyla Baltazar-López; Sergio Islas-Andrade; Galileo Escobedo; Guillermo Meléndez Journal: J Immunol Res Date: 2019-04-28 Impact factor: 4.818